Patents Represented by Attorney Charles W. Ashbrook

Find this attorney in the Justia Lawyer Directory

  • Cycloalkyl inhibitors of protein farnesyltransferase
    Patent number: 6281194
    Abstract: Novel inhibitors of protein farnesyltransferase enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in controlling tissue proliferative diseases, including cancer, restenosis, atherosclerosis, psoriasis and endometriosis.
    Type: Grant
    Filed: June 2, 1999
    Date of Patent: August 28, 2001
    Assignee: Warner-Lambert Company
    Inventors: Annette M. Doherty, James S. Kaltenbronn, Daniele M. Leonard, Dennis J. McNamara
  • Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
    Patent number: 6268387
    Abstract: The present invention provides compounds of formula (I). The present invention also provides methods of treating or preventing inflammation or atherosclerosis, and a pharmaceutical composition that contains a compound of formula (I).
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: July 31, 2001
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, William Howard Roark, Karen Elaine Sexton, Roderick Joseph Sorenson
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Patent number: 6265399
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6265422
    Abstract: The present invention provides compounds of Formula I The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Dipeptide inhibitors of protein farnesyltransferase
    Patent number: 6265382
    Abstract: The present invention provides compounds having the structure represented by formula (I). Also provided is a method of treating cancer, restenosis, atherosclerosis, or psoriasis or preventing restenosis, and a pharmaceutical composition comprising a compound of formula (I).
    Type: Grant
    Filed: June 28, 1999
    Date of Patent: July 24, 2001
    Assignee: Warner-Lambert Company
    Inventors: Annette Marian Doherty, Daniele Marie Leonard, Dennis Joseph McNamara, Kevon Ray Shuler
  • Prodrugs of benzofuranylethyl carbamate NK1 antagonists
    Patent number: 6258800
    Abstract: The instant invention provides aqueous soluble prodrugs of formula (I) or a pharmaceutically acceptable salt thereof wherein R is —CH2OZ, —C(═O)OCH2OZ or Z, wherein Z is formula (a), —P(═O)(OH)2 or —C(═O)Q: n is an integer of from 0 to 3; m is an integer of from 0 to 1, of certain tachykinin antagonists (NK1 antagonists) useful in the treatment of emesis.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: July 10, 2001
    Assignee: Warner-Lambert Company
    Inventors: Michael Huai Gu Chen, Om Prakash Goel, Fred M. Hershenson, Zhijian Zhu, Oilun Helen Chan
  • Method of treating or preventing septic shock by administering a MEK inhibitor
    Patent number: 6251943
    Abstract: The present invention provides a method for treating or preventing septic shock. Specifically, the present invention provides a method of treating or preventing septic shock by administering to a patient a MEK inhibitor.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Douglas Barrett, Alexander James Bridges, Donna Reynolds Cody, Annette Marian Doherty, David Thomas Dudley, Alan Robert Saltiel, Mel Conrad Schroeder, Haile Tecle
  • Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
    Patent number: 6252070
    Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1 The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
  • Heterocyclic substituted aniline calcium channel blockers
    Patent number: 6251919
    Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, epilepsy, asthma, amyotrophic lateral sclerosis, or pain and to pharmaceutical compositions that contain the compounds of Formula I.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert
    Inventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder
  • Protein targeting to glycogen
    Patent number: 6252057
    Abstract: The present invention provides human and murine genomic and complementary DNA and the proteins that are encoded by the DNA, which is called “Protein Targeting to Glycogen”. Also provided is a method of increasing the amount of glycogen in a cell.
    Type: Grant
    Filed: February 25, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Matthew Jemail Brady, John Andrew Printen, Alan Robert Saltiel
  • Aniline derivatives as calcium channel blockers
    Patent number: 6251918
    Abstract: The present invention provides compounds that block calcium channels having formula (I). The present invention also provides methods of using the compounds of formula (I) to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of formula (I).
    Type: Grant
    Filed: September 29, 1999
    Date of Patent: June 26, 2001
    Assignee: Warner-Lambert Company
    Inventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder
  • Crystalline sodium phenytoin monohydrate
    Patent number: 6245917
    Abstract: Crystalline sodium phenytoin monohydrate is stable, nonhygroscopic, and water soluble.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: June 12, 2001
    Assignee: Warner-Lambert Company
    Inventors: Robert Lee Bosch, Peter Raymond Johnson, Robert Joseph Stahl
  • Method for preventing and treating pain
    Patent number: 6242488
    Abstract: GABA analogs are useful to prevent and treat gastrointestinal damage and ethanol withdrawal syndrome. Preferred treatments employ gabapentin or pregabalin.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: June 5, 2001
    Assignees: University of Oklahoma, Warner-Lambert Company
    Inventors: Lionel Bueno, Maria Chovet, Laurent Diop, Antonio Guglietta, Hilary J. Little, Michael Francis Rafferty, Jiayuan Ren, Charles Price Taylor, Jr., William Patrick Watson
  • Phosphodiesterase 4-inhibiting diazepinoindolones
    Patent number: 6239130
    Abstract: The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent or treat asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, septic shock, or multiple sclerosis, and to pharmaceutical compositions that contain the compounds of Formula (I).
    Type: Grant
    Filed: November 10, 1999
    Date of Patent: May 29, 2001
    Assignee: Warner-Lambert Company
    Inventors: Yves Pascal, Catherine Burnouf, Bernard Gaudilliere, Henry Jacobelli, Alain Calvet, Adrian Payne, Svein Dahl
  • Method of inhibiting connective tissue degradation
    Patent number: 6211209
    Abstract: The present invention provides a method of inhibiting connective tissue degradation that comprises administering to a patient having a condition in which connective tissue is degraded a therapeutically effective amount of a compound having the formula where R1, R2, R3, and R4 are independently hydrogen, hydroxy, halo, amino, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, CF3, CN, S(O)n—, R6 and R7 are independently hydrogen, C1-C6 alkyl, or acyl; n is 0 to 2; R8 is hydrogen or C1-C6 alkyl; W is S or O; Z is C1-C6 alkyl, C1-C6 alkoxy, or NR9R10; R9 and R10 are independently hydrogen or C1-C6 alkyl; and R5 is where Y is hydroxy, thiol, amino, or NHCN; X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: April 3, 2001
    Assignee: Warner-Lambert Company
    Inventors: Vijaykumar Baragi, Diane Harris Boschelli, David Thomas Connor, Richard Raymond Renkiewicz, Howard Glenn Welgus
  • Composition for the delivery of a pharmaceutical agent to a patient
    Patent number: 6207172
    Abstract: The present invention relates to a composition for the delivery of a pharmaceutical agent to a patient that comprises polyethylene glycol, an aqueous solution containing polyvinylpyrrolidone, and a pharmaceutical agent. The invention also relates to methods of making a composition for the delivery of a pharmaceutical agent.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: March 27, 2001
    Assignee: Warner-Lambert Company
    Inventors: Howard Yoshihisa Ando, Steven Edward Rose
  • Gamma amino butyric acid analogs and optical isomers
    Patent number: 6197819
    Abstract: A compound of the formula wherein R1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R2 is hydrogen or methyl; and R3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: March 6, 2001
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Ryszard Andruszkiewicz
  • Hexahydro-naphthalenone oximes and hydrazones
    Patent number: 6187808
    Abstract: This invention provides 6-amino-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one oximes and hydrazones which are useful in treating Parkinson's disease.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: February 13, 2001
    Assignee: Warner-Lambert Company
    Inventors: Stephen Joseph Johnson, Leonard Theodore Meltzer, Lawrence David Wise
  • Tyrosine-derived compounds as calcium channel antagonists
    Patent number: 6180677
    Abstract: The present invention provides compounds that block calcium channels and have the Formula I: and pharmaceutically acceptable salts, esters, and pro-drugs thereof, wherein R1 and R2 are independently H, phenylcyclopentylcarbonyl, C1-C7 alkyl, cyclohexylmethyl, benzyl, C1-C5 alkylbenzyl, or C1-C5 alkoxybenzyl, A is —C(O)— or —CH2—; R3 is H or —CH3; R4 is C1-C4 alkyl or piperidin-1-ylethyl; R5 is phenyl-(CH2)n—, C1-C4 alkylphenyl-(CH2)n—, or halophenyl-(CH2)n—; and n is 1 or 2. The present invention also provides pharmaceutical compositions containing the compounds of Formula I and methods of using them to treat stroke, cerebral ischemia, head trauma, and epilepsy.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: January 30, 2001
    Assignee: Warner-Lambert Company
    Inventors: Michael Francis Rafferty, Yuntao Song
  • Benzoxazinone dopamine D4 receptor antagonists
    Patent number: 6177422
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: January 23, 2001
    Assignee: Warner-Lambert Company
    Inventors: Thomas R. Belliotti, Lawrence D. Wise, David J. Wustrow